Orion Pharma (DHA:ORIONPHARM) Other Current Assets: BDT924 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT30.30
GF Value BDT20.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Other Current Assets?

Orion Pharma DHA:ORIONPHARM +0.66% 72 Other Current Assets is BDT924 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.17 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's other current assets for the quarter that ended in Mar. 2026 was BDT924 Mil.

Orion Pharma's quarterly other current assets increased from Sep. 2025 (BDT867 Mil) to Dec. 2025 (BDT911 Mil) and increased from Dec. 2025 (BDT911 Mil) to Mar. 2026 (BDT924Mil).

Orion Pharma's annual other current assets declined from Jun. 2023 (BDT1,898 Mil) to Jun. 2024 (BDT1,045 Mil) declined from Jun. 2024 (BDT1,045 Mil) to Jun. 2025 (BDT860 Mil).


Orion Pharma Other Current Assets Related Terms


Orion Pharma Other Current Assets Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Other Current Assets Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,972.26 2,051.73 1,897.89 1,044.80 859.62

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 911.95 859.62 867.23 910.82 923.75
DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of BDT924 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Other Current Assets of BDT924 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Orion Pharma.
Is Orion Pharma's Other Current Assets too high?
Orion Pharma's current Other Current Assets is BDT924 Mil. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Other Current Assets compare to CEG and VST?
Orion Pharma's Other Current Assets of BDT924 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for an Utilities - Independent Power Producers company?
A good Other Current Assets depends on the Utilities - Independent Power Producers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Orion Pharma. Orion Pharma's current Other Current Assets is BDT924 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.17, compared to a current price of BDT30.30 — trading 50.2% above its estimated fair value. The current Other Current Assets is BDT924 Mil. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Other Current Assets is BDT924 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.30 is trading 50.2% above its estimated GF Value™ of BDT20.17. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Other Current Assets: BDT924 Mil
  • GF Value™: BDT20.17 vs. price of BDT30.30 (50.2% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.30
Price
BDT20.17
GF Value